Floatz logo

Dat-2645

HRD Cancer

Danatlas Pharmaceuticals Co., LtdPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the HRD Cancer cohort.

Asset / SponsorPhaseRating
vx-970
National Cancer Institute (NCI)
Phase 1/2CCC

Same molecule, other indications

Dat-2645 is also rated in:

ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
Solid CancersDormant
CC
Indicative ·
43 / 100
View asset →
BRCA MutationDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →